At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
rifaximinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy
Centre Hospitalier Universitaire Saint Pierre·interventional·Posted Jun 16, 2014·Updated May 1, 2019
In Brief
A clinical study evaluating rifaximine for Hepatic Encephalopathy. Completed, enrolled 15 participants across 1 site.
Detailed Summary
Hepatic encephalopathy is responsible for sleep disturbances and daytime sleepiness. The purpose of our study is to assess sleep quality, quantity, sleep schemes and physical activity in patients suffering from HE, before and after a 2 weeks treatment with rifaximine, which is currently given to lower blood ammoniac levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Encephalopathy
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedJun 2014
Primary CompletionJul 2015
TodayJul 2026
First PostedJun 16, 2014
Enrollment StartMar 1, 2014
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.0 years ago
Interventions
rifaximinedrug